Atopic Dermatitis
1,062
120
169
629
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
236 trials with published results (22%)
Research Maturity
629 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.3%
78 terminated out of 1062 trials
89.0%
+2.5% vs benchmark
23%
242 trials in Phase 3/4
38%
236 of 629 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 629 completed trials
Clinical Trials (1062)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Subjects Affected by Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks
Characterization of Chronic Hand Eczema
Effects of an Emollient Containing Postbiotic Saccharomyces and Lactobacillus on Pediatric Atopic Dermatitis
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
A Study Evaluating TRIV-509 in Atopic Dermatitis